<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Haematol</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Haematol</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1365-2141</journal-id><journal-id journal-id-type="publisher-id">BJH</journal-id><journal-title-group><journal-title>British Journal of Haematology</journal-title></journal-title-group><issn pub-type="ppub">0007-1048</issn><issn pub-type="epub">1365-2141</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29602208</article-id><article-id pub-id-type="pmc">6766952</article-id><article-id pub-id-type="doi">10.1111/bjh.15155</article-id><article-id pub-id-type="publisher-id">BJH15155</article-id><article-categories><subj-group subj-group-type="overline"><subject>Correspondence</subject></subj-group><subj-group subj-group-type="heading"><subject>Correspondence</subject></subj-group></article-categories><title-group><article-title>Recurrent histone mutations in T&#x02010;cell acute lymphoblastic leukaemia</article-title><alt-title alt-title-type="left-running-head">Correspondence</alt-title></title-group><contrib-group><contrib id="bjh15155-cr-0001" contrib-type="author"><name><surname>Collord</surname><given-names>Grace</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1924-4411</contrib-id><xref ref-type="aff" rid="bjh15155-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="bjh15155-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="bjh15155-cr-0002" contrib-type="author"><name><surname>Martincorena</surname><given-names>Inigo</given-names></name><xref ref-type="aff" rid="bjh15155-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="bjh15155-cr-0003" contrib-type="author"><name><surname>Young</surname><given-names>Matthew D.</given-names></name><xref ref-type="aff" rid="bjh15155-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="bjh15155-cr-0004" contrib-type="author"><name><surname>Foroni</surname><given-names>Letizia</given-names></name><xref ref-type="aff" rid="bjh15155-aff-0003">
<sup>3</sup>
</xref><xref ref-type="aff" rid="bjh15155-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="bjh15155-cr-0005" contrib-type="author"><name><surname>Bolli</surname><given-names>Niccolo</given-names></name><xref ref-type="aff" rid="bjh15155-aff-0005">
<sup>5</sup>
</xref><xref ref-type="aff" rid="bjh15155-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="bjh15155-cr-0006" contrib-type="author"><name><surname>Stratton</surname><given-names>Michael R.</given-names></name><xref ref-type="aff" rid="bjh15155-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="bjh15155-cr-0007" contrib-type="author"><name><surname>Vassiliou</surname><given-names>George S.</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4337-8022</contrib-id><xref ref-type="aff" rid="bjh15155-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="bjh15155-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="bjh15155-cr-0008" contrib-type="author"><name><surname>Campbell</surname><given-names>Peter J.</given-names></name><address><email>pc8@sanger.ac.uk</email></address><xref ref-type="aff" rid="bjh15155-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="bjh15155-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="bjh15155-cr-0009" contrib-type="author"><name><surname>Behjati</surname><given-names>Sam</given-names></name><address><email>sb31@sanger.ac.uk</email></address><xref ref-type="aff" rid="bjh15155-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="bjh15155-aff-0002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="bjh15155-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Wellcome Trust Sanger Institute</named-content>
<institution>Wellcome Trust Genome Campus</institution>
<named-content content-type="city">Hinxton</named-content>
<named-content content-type="country-part">Cambridgeshire</named-content>
<country country="GB">UK</country>
</aff><aff id="bjh15155-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Paediatrics</named-content>
<institution>University of Cambridge</institution>
<named-content content-type="city">Cambridge</named-content>
<country country="GB">UK</country>
</aff><aff id="bjh15155-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Centre for Haematology</named-content>
<named-content content-type="organisation-division">Faculty of Medicine</named-content>
<institution>Imperial College London</institution>
<named-content content-type="city">London</named-content>
<country country="GB">UK</country>
</aff><aff id="bjh15155-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Clinical Haematology</named-content>
<institution>Imperial College Healthcare NHS Trust</institution>
<named-content content-type="city">London</named-content>
<country country="GB">UK</country>
</aff><aff id="bjh15155-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Department of Oncology and Haemato&#x02010;Oncology</named-content>
<institution>University of Milan</institution>
<named-content content-type="city">Milan</named-content>
<country country="IT">Italy</country>
</aff><aff id="bjh15155-aff-0006">
<label><sup>6</sup></label>
<named-content content-type="organisation-division">Department of Oncology and Haematology</named-content>
<institution>Fondazione IRCCS Istituto Nazionale dei Tumori</institution>
<named-content content-type="city">Milan</named-content>
<country country="IT">Italy</country>
</aff><aff id="bjh15155-aff-0007">
<label><sup>7</sup></label>
<named-content content-type="organisation-division">Department of Haematology</named-content>
<institution>University of Cambridge</institution>
<named-content content-type="city">Cambridge</named-content>
<country country="GB">UK</country>
</aff><pub-date pub-type="epub"><day>30</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2019</year></pub-date><volume>184</volume><issue>4</issue><issue-id pub-id-type="doi">10.1111/bjh.2019.184.issue-4</issue-id><fpage>676</fpage><lpage>679</lpage><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2019 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2018 The Authors. <italic>British Journal of Haematology</italic> published by British Society for Haematology and John Wiley &#x00026; Sons Ltd</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:BJH-184-676.pdf"/><kwd-group kwd-group-type="author-generated"><kwd id="bjh15155-kwd-0001">acute leukaemia</kwd><kwd id="bjh15155-kwd-0002">cancer genetics</kwd><kwd id="bjh15155-kwd-0003">aetiology</kwd><kwd id="bjh15155-kwd-0004">haematological malignancy</kwd></kwd-group><funding-group><award-group><funding-source>Wellcome Trust</funding-source></award-group><award-group><funding-source>Wellcome Trust Intermediate Clinical Research Fellowship</funding-source></award-group><award-group><funding-source>St. Baldrick's Foundation Robert J. Arceci Innovation Award</funding-source></award-group><award-group><funding-source>Wellcome Trust Clinical PhD Fellowship</funding-source><award-id>WT098051</award-id></award-group><award-group><funding-source>AIRC (Associazione Italiana per la Ricerca sul Cancro)</funding-source><award-id>WT088340MA</award-id></award-group><award-group><funding-source>MFAG</funding-source><award-id>17658</award-id></award-group><award-group><funding-source>Wellcome Trust Senior Fellowship in Clinical Science</funding-source><award-id>WT095663MA</award-id></award-group><award-group><funding-source>Wellcome Trust Senior Clinical Research Fellowship</funding-source><award-id>WT088340MA</award-id></award-group></funding-group><counts><fig-count count="1"/><table-count count="1"/><page-count count="4"/><word-count count="2132"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>bjh15155</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2019</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.9 mode:remove_FC converted:30.09.2019</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="bjh15155-ntgp-2100"><fn id="bjh15155-note-1201"><p>The copyright line for this article was changed on 9 July 2019 after original online publication.</p></fn></fn-group></notes></front><body><p>Mutations affecting key modifiable histone type 3 (H3; Table&#x000a0;<xref rid="bjh15155-sup-0002" ref-type="supplementary-material">SI</xref>) residues are frequent oncogenic events in certain solid tumours (Feinberg <italic>et&#x000a0;al</italic>, <xref rid="bjh15155-bib-0004" ref-type="ref">2016</xref>), and have also recently been implicated in a subset of acute myeloid leukaemia (AML) (Lehnertz <italic>et&#x000a0;al</italic>, <xref rid="bjh15155-bib-0007" ref-type="ref">2017</xref>). Here, we systematically reviewed the somatic mutations in &#x0003e;20&#x000a0;000 cancer specimens to identify tumours harbouring H3 mutations. In a subset of T&#x02010;cell acute lymphoblastic leukaemia (T&#x02010;ALL) we identified non&#x02010;methionine mutations of the key modifiable H3 residues, lysine (K) 27 and 36.</p><p>The starting point of our investigation was a search for H3 hotspot mutations in 1020 human cancer cell lines (Table&#x000a0;<xref rid="bjh15155-sup-0003" ref-type="supplementary-material">SII</xref>). In two cell lines, both derived from T&#x02010;ALL, we found lysine&#x02010;to&#x02010;arginine mutations at H3K27 and H3K36 (Table&#x000a0;<xref rid="bjh15155-tbl-0001" ref-type="table">1</xref>). One of the cell lines, LOUCY, is derived from a <italic>NOTCH1</italic> wild&#x02010;type adult T&#x02010;ALL (Ben&#x02010;Bassat <italic>et&#x000a0;al</italic>, <xref rid="bjh15155-bib-0003" ref-type="ref">1990</xref>). The second, CML&#x02010;T1, was derived from the T&#x02010;lymphoblastic blast crisis of chronic myeloid leukaemia (Kuriyama <italic>et&#x000a0;al</italic>, <xref rid="bjh15155-bib-0006" ref-type="ref">1989</xref>). Ten further T&#x02010;ALL cell lines lacked coding H3 mutations (Table&#x000a0;<xref rid="bjh15155-sup-0004" ref-type="supplementary-material">SIII</xref>). In solid tumours, H3K27 and H3K36 are typically mutated to methionine (Fig&#x000a0;<xref rid="bjh15155-fig-0001" ref-type="fig">1</xref>) (Feinberg <italic>et&#x000a0;al</italic>, <xref rid="bjh15155-bib-0004" ref-type="ref">2016</xref>). However, recent functional studies of H3 lysine&#x02010;to&#x02010;isoleucine mutations in AML demonstrate that the latter also dramatically alter global H3 methylation and acetylation patterns (Lehnertz <italic>et&#x000a0;al</italic>, <xref rid="bjh15155-bib-0007" ref-type="ref">2017</xref>). Therefore, we speculated that lysine&#x02010;to&#x02010;non&#x02010;methionine mutations may also be drivers of a subset of T&#x02010;ALL.</p><table-wrap id="bjh15155-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Type 3 histone mutations in T cell leukaemia</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Sample name</th><th align="left" valign="top" rowspan="1" colspan="1">Sample type</th><th align="left" valign="top" rowspan="1" colspan="1">Donor age (years)</th><th align="left" valign="top" rowspan="1" colspan="1">Donor sex</th><th align="left" valign="top" rowspan="1" colspan="1">H3 mutation</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">LOUCY</td><td align="left" rowspan="1" colspan="1">Cell line derived from ETP&#x02010;ALL</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">
<italic>HIST1H3G</italic> p.K36R</td></tr><tr><td align="left" rowspan="1" colspan="1">CML&#x02010;T1</td><td align="left" rowspan="1" colspan="1">Cell line derived from the acute T&#x02010;lympoblastic blast crisis of CML</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">
<italic>H3F3A</italic> p.K27R</td></tr><tr><td align="left" rowspan="1" colspan="1">SJTALL174</td><td align="left" rowspan="1" colspan="1">Primary ETP&#x02010;ALL specimen</td><td align="left" rowspan="1" colspan="1">Unknown (paediatric)</td><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">
<italic>H3F3A</italic> p.K36R</td></tr><tr><td align="left" rowspan="1" colspan="1">SJTALL080</td><td align="left" rowspan="1" colspan="1">Primary T&#x02010;ALL specimen</td><td align="left" rowspan="1" colspan="1">Unknown (paediatric)</td><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">
<italic>H3F3A</italic> p.K27R</td></tr><tr><td align="left" rowspan="1" colspan="1">PD2752a</td><td align="left" rowspan="1" colspan="1">Primary T&#x02010;ALL specimen</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">
<italic>H3F3A</italic> p.K27N</td></tr></tbody></table><table-wrap-foot><fn id="bjh15155-note-0001"><p>Out of 141 T cell leukaemia specimens screened (12 cell lines and 129 primary samples), 5 (3&#x000b7;5%) harboured a missense mutation at a modifiable lysine residues K27 or K36. CML, chronic myeloid leukaemia; ETP&#x02010;ALL, early T cell precursor acute lymphoblastic leukaemia; T&#x02010;ALL, T cell acute lymphoblastic leukaemia.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><fig fig-type="Figure" xml:lang="en" id="bjh15155-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Prevalence and amino acid specificity of type 3 histone mutations in different cancer types. Columns indicate cancer types and rows show key histone type 3 regulatory residues. Tiles are coloured according to amino acid substitution. The percentage of each tumour type affected by the given class of histone mutation is indicated within the tiles and the overall prevalence of histone mutations is summarised at the bottom of each column. <styled-content style="fixed-case">NBS HGG</styled-content>, non&#x02010;brain stem high grade glioma; <styled-content style="fixed-case">DIPG</styled-content>, diffuse intrinsic pontine glioma; <styled-content style="fixed-case">ASTR</styled-content>, astrocytoma; <styled-content style="fixed-case">AML</styled-content>, acute myeloid leukaemia; T&#x02010;<styled-content style="fixed-case">ALL</styled-content>, T cell acute lymphoblastic leukaemia; <styled-content style="fixed-case">OS</styled-content>, osteosarcoma; <styled-content style="fixed-case">ADM</styled-content>, adamantinoma; <styled-content style="fixed-case">GCTB</styled-content>, giant cell tumour of bone; <styled-content style="fixed-case">CCC</styled-content>, clear cell chondrosarcoma; <styled-content style="fixed-case">CB</styled-content>, chondroblastoma; <styled-content style="fixed-case">CS</styled-content>, chondrosarcoma.</p></caption><graphic id="nlm-graphic-1" xlink:href="BJH-184-676-g001"/></fig><p>We next searched for canonical H3 mutations in a published targeted sequencing study of 633 epigenetic regulator genes in &#x0003e;1000 childhood tumours encompassing 21 cancer subtypes (Huether <italic>et&#x000a0;al</italic>, <xref rid="bjh15155-bib-0005" ref-type="ref">2014</xref>). Amongst 91 T&#x02010;ALL specimens, there were two cases with canonical H3 mutations: <italic>H3F3A</italic> p.K27R and <italic>H3F3A</italic> p.K36R (Table&#x000a0;I). Both mutations were clonal, with a variant allele fraction (VAF) of 38% and 55%, respectively. Among the 37 tumours with H3K mutations, lysine&#x02010;to&#x02010;arginine mutations were restricted to T&#x02010;ALL (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;001502; Fisher's exact test).</p><p>We then extended our screen for H3 mutations to 18&#x000a0;704 tumours, encompassing &#x0003e;60 cancer types other than T&#x02010;ALL (Tables <xref rid="bjh15155-sup-0005" ref-type="supplementary-material">SIV</xref> and <xref rid="bjh15155-sup-0006" ref-type="supplementary-material">SV</xref>). This dataset comprised 8764 internally sequenced specimens and 9940 TCGA samples re&#x02010;analysed using an in&#x02010;house variant calling pipeline as previously described (Martincorena <italic>et&#x000a0;al</italic>, <xref rid="bjh15155-bib-0008" ref-type="ref">2017</xref>). We identified only one neomorphic H3 mutation in an acute leukaemia specimen: a previously reported <italic>HIST1H3D</italic> p.K27M mutation in an adult AML case (TCGA&#x02010;AB2927&#x02010;03) (Lehnertz <italic>et&#x000a0;al</italic>, <xref rid="bjh15155-bib-0007" ref-type="ref">2017</xref>).</p><p>Finally, we examined an additional T&#x02010;ALL cohort by capillary sequencing of recurrently mutated modifiable residues K27, G34, and K36 across four frequently mutated H3 genes (Tables <xref rid="bjh15155-sup-0007" ref-type="supplementary-material">SVI</xref> and <xref rid="bjh15155-sup-0008" ref-type="supplementary-material">SVII</xref>). The cohort comprised 38 T&#x02010;ALL cases described in detail previously (Maser <italic>et&#x000a0;al</italic>, <xref rid="bjh15155-bib-0009" ref-type="ref">2007</xref>). One specimen from a 30&#x02010;year&#x02010;old patient harboured a <italic>H3F3A</italic> p.K27N mutation (Figure&#x000a0;<xref rid="bjh15155-sup-0001" ref-type="supplementary-material">S1</xref>). Interestingly, a <italic>H3F3A</italic> p.K27N mutation and a <italic>H3F3A</italic> p.K27T variant were previously identified in a T&#x02010;ALL RNA sequencing study (<italic>n</italic>&#x000a0;=&#x000a0;31) (Atak <italic>et&#x000a0;al</italic>, <xref rid="bjh15155-bib-0001" ref-type="ref">2013</xref>). Collectively, our findings indicate that H3K27 and H3K36 mutations are recurrent in T&#x02010;ALL, a result we were able to reproduce across multiple different cohorts encompassing adult and paediatric cases.</p><p>This finding is congruent with the fact that mutations in <italic>SETD2</italic> and <italic>EZH2</italic>, methyltransferases that catalyse trimethylation (me3) of H3K36 and H3K27, respectively, are frequent T&#x02010;ALL drivers (Belver &#x00026; Ferrando, <xref rid="bjh15155-bib-0002" ref-type="ref">2016</xref>). Disruptive <italic>SETD2</italic> alterations occur in 7&#x000b7;8% of early T cell precursor acute lymphoblastic leukaemia (ETP&#x02010;ALL), an aggressive subtype with stem cell&#x02010;like features (Belver &#x00026; Ferrando, <xref rid="bjh15155-bib-0002" ref-type="ref">2016</xref>). Interestingly, both T&#x02010;ALL specimens with H3K36R mutations originated from ETP&#x02010;ALL (Table&#x000a0;<xref rid="bjh15155-tbl-0001" ref-type="table">1</xref>). Notably, mutually exclusive <italic>SETD2</italic> and H3K36/H3K34 mutations are reported in paediatric high grade glioma, where both result in reduced H3K36me3 mediated by <italic>SETD2</italic> (Feinberg <italic>et&#x000a0;al</italic>, <xref rid="bjh15155-bib-0004" ref-type="ref">2016</xref>). It is unclear whether a similar co&#x02010;mutation pattern exists in T&#x02010;ALL, as H3 genes have not been included in targeted sequencing panels used by the largest T&#x02010;ALL genomic studies (Belver &#x00026; Ferrando, <xref rid="bjh15155-bib-0002" ref-type="ref">2016</xref>).</p><p>The role of H3K27 modifications in T&#x02010;ALL pathogenesis is complex (Belver &#x00026; Ferrando, <xref rid="bjh15155-bib-0002" ref-type="ref">2016</xref>). It is plausible that mutations affecting this residue could impact the activity of several histone modifiers with established roles in T&#x02010;ALL pathogenesis. Loss&#x02010;of&#x02010;function mutations in <italic>EZH2</italic> or other core components of Polycomb repressive complex 2 (PRC2) are found in 42% of ETP&#x02010;ALL and 25% of T&#x02010;ALL overall (Belver &#x00026; Ferrando, <xref rid="bjh15155-bib-0002" ref-type="ref">2016</xref>). Impaired PRC2 catalytic activity in T&#x02010;ALL is associated with reduced H3K27me3, stemness and poor prognosis (Belver &#x00026; Ferrando, <xref rid="bjh15155-bib-0002" ref-type="ref">2016</xref>). <italic>H3F3A</italic> p.K27M mutations appear to act predominantly by blocking H3K27 di&#x02010; and trimethylation and increasing H3K27 acetylation (Feinberg <italic>et&#x000a0;al</italic>, <xref rid="bjh15155-bib-0004" ref-type="ref">2016</xref>). Recent work demonstrates that H3K27I mutations in AML are associated with similar changes in H3 modification patterns (Lehnertz <italic>et&#x000a0;al</italic>, <xref rid="bjh15155-bib-0007" ref-type="ref">2017</xref>), suggesting that other non&#x02010;methionine mutations at modifiable H3 residues may influence the activity of PRC2 and other histone modifying enzymes. The lysine&#x02010;specific demethylases <italic>JMJD3</italic> and <italic>UTX</italic> are further important regulators of H3K27me3 distribution in T&#x02010;ALL (Belver &#x00026; Ferrando, <xref rid="bjh15155-bib-0002" ref-type="ref">2016</xref>), and it is conceivable that these enzymes may also be affected by H3K27 or H3K36 mutations.</p><p>A feature of H3 mutations in solid cancers is their exquisite tumour type specificity (Fig&#x000a0;<xref rid="bjh15155-fig-0001" ref-type="fig">1</xref>) (Feinberg <italic>et&#x000a0;al</italic>, <xref rid="bjh15155-bib-0004" ref-type="ref">2016</xref>). In this context, it is notable that 5/5 H3 mutations in T&#x02010;ALL identified by this survey are lysine&#x02010;to&#x02010;non&#x02010;methionine mutations, and 4/5 are lysine&#x02010;to&#x02010;arginine mutations. Out of the &#x0003e;20&#x000a0;000 tumour specimens screened for H3 variants, only two other samples harboured H3 lysine&#x02010;to&#x02010;arginine mutations, both at low VAF and in tumours with relatively high coding mutation burdens (TCGA&#x02010;BT&#x02010;A20Q&#x02010;01 and TCGA&#x02010;AN&#x02010;A0FW&#x02010;01). Hence, it is possible that lysine&#x02010;to&#x02010;arginine mutations confer particular selective advantage in the context of T cell leukaemogenesis.</p><p>In summary, ~3% of T&#x02010;ALL harbour non&#x02010;methionine variants in H3 genes at key modifiable lysine residues. Given the role of dysregulated H3K27/H3K36 modification in T&#x02010;ALL pathogenesis and the established prognostic significance of mutations in lysine&#x02010;specific histone modifiers (Belver &#x00026; Ferrando, <xref rid="bjh15155-bib-0002" ref-type="ref">2016</xref>), this finding warrants further investigation of the prevalence, clinical and functional significance of H3 mutations in T&#x02010;ALL. In light of the recent discovery of oncogenic H3K37 mutations in AML (Lehnertz <italic>et&#x000a0;al</italic>, <xref rid="bjh15155-bib-0007" ref-type="ref">2017</xref>), our findings suggest a broader role for histone mutations in acute leukaemias and clearly justify incorporation of H3 genes into haematological cancer sequencing panels.</p><sec id="bjh15155-sec-0003"><title>Authorship</title><p>S.B., M.R.S. and P.J.C. conceived and designed the study. G.C. and S.B. performed analysis with input from M.Y., I.M. and N.B. L.F. contributed materials. G.C. and S.B. wrote the manuscript with contributions from G.S.V. and P.J.C.</p></sec><sec sec-type="COI-statement" id="bjh15155-sec-0004"><title>Conflict of interest</title><p>The authors have no competing financial interests to declare.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="bjh15155-sup-0001"><caption><p>
<bold>Figure&#x000a0;S1.</bold> Histone 3 mutation in T&#x02010;ALL validation cohort.</p></caption><media xlink:href="BJH-184-676-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="bjh15155-sup-0002"><caption><p>
<bold>Table&#x000a0;SI</bold>. Type 3 histone genes.</p></caption><media xlink:href="BJH-184-676-s002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="bjh15155-sup-0003"><caption><p>
<bold>Table&#x000a0;SII.</bold> COSMIC version 81 cell lines screened for type 3 histone mutations.</p></caption><media xlink:href="BJH-184-676-s003.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="bjh15155-sup-0004"><caption><p>
<bold>Table&#x000a0;SIII.</bold> T&#x02010;cell leukaemia lines screened for type 3 histone mutations.</p></caption><media xlink:href="BJH-184-676-s004.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="bjh15155-sup-0005"><caption><p>
<bold>Table&#x000a0;SIV.</bold> Internal database screened for histone 3 mutations.</p></caption><media xlink:href="BJH-184-676-s005.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="bjh15155-sup-0006"><caption><p>
<bold>Table&#x000a0;SV.</bold> TCGA cohort screened for histone 3 mutations.</p></caption><media xlink:href="BJH-184-676-s006.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="bjh15155-sup-0007"><caption><p>
<bold>Table&#x000a0;SVI.</bold> Validation cohort of 38 primary human T&#x02010;ALL specimens screened by Sanger sequencing of histone 3 genes.</p></caption><media xlink:href="BJH-184-676-s007.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="bjh15155-sup-0008"><caption><p>
<bold>Table&#x000a0;SVII.</bold> Primers used to Sanger sequence hotspot residues in histone 3 genes.</p></caption><media xlink:href="BJH-184-676-s008.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="bjh15155-sec-0002"><title>Acknowledgments</title><p>This work was supported by the Wellcome Trust. S.B. was funded by a Wellcome Trust Intermediate Clinical Research Fellowship and a St. Baldrick's Foundation Robert J. Arceci Innovation Award; G.C. by a Wellcome Trust Clinical PhD Fellowship (WT098051); N.B. by AIRC (Associazione Italiana per la Ricerca sul Cancro) through a MFAG (n.17658); G.S.V by a Wellcome Trust Senior Fellowship in Clinical Science (WT095663MA) and P.J.C. by a Wellcome Trust Senior Clinical Research Fellowship (WT088340MA). We thank Professor Adele Fielding for providing samples.</p></ack><ref-list content-type="cited-references" id="bjh15155-bibl-0001"><title>References</title><ref id="bjh15155-bib-0001"><mixed-citation publication-type="journal" id="bjh15155-cit-0001">
<string-name>
<surname>Atak</surname>, <given-names>Z.K.</given-names>
</string-name>, <string-name>
<surname>Gianfelici</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Hulselmans</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>De Keersmaecker</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Devasia</surname>, <given-names>A.G.</given-names>
</string-name>, <string-name>
<surname>Geerdens</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Mentens</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Chiaretti</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Durinck</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Uyttebroeck</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Vandenberghe</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Wlodarska</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Cloos</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Foa</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Speleman</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Cools</surname>, <given-names>J.</given-names>
</string-name> &#x00026; <string-name>
<surname>Aerts</surname>, <given-names>S.</given-names>
</string-name> (<year>2013</year>) <article-title>Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T&#x02010;cell acute lymphoblastic leukemia</article-title>. <source xml:lang="en">PLoS Genetics</source>, <volume>9</volume>, <fpage>e1003997</fpage>.<pub-id pub-id-type="pmid">24367274</pub-id></mixed-citation></ref><ref id="bjh15155-bib-0002"><mixed-citation publication-type="journal" id="bjh15155-cit-0002">
<string-name>
<surname>Belver</surname>, <given-names>L.</given-names>
</string-name> &#x00026; <string-name>
<surname>Ferrando</surname>, <given-names>A.</given-names>
</string-name> (<year>2016</year>) <article-title>The genetics and mechanisms of T cell acute lymphoblastic leukaemia</article-title>. <source xml:lang="en">Nature Reviews Cancer</source>, <volume>16</volume>, <fpage>494</fpage>&#x02013;<lpage>507</lpage>.<pub-id pub-id-type="pmid">27451956</pub-id></mixed-citation></ref><ref id="bjh15155-bib-0003"><mixed-citation publication-type="journal" id="bjh15155-cit-0003">
<string-name>
<surname>Ben&#x02010;Bassat</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Shlomai</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Kohn</surname>, <given-names>G.</given-names>
</string-name> &#x00026; <string-name>
<surname>Prokocimer</surname>, <given-names>M.</given-names>
</string-name> (<year>1990</year>) <article-title>Establishment of a human T&#x02010;acute lymphoblastic leukemia cell line with a (16;20) chromosome translocation</article-title>. <source xml:lang="en">Cancer Genetics and Cytogenetics</source>, <volume>49</volume>, <fpage>241</fpage>&#x02013;<lpage>248</lpage>.<pub-id pub-id-type="pmid">2208060</pub-id></mixed-citation></ref><ref id="bjh15155-bib-0004"><mixed-citation publication-type="journal" id="bjh15155-cit-0004">
<string-name>
<surname>Feinberg</surname>, <given-names>A.P.</given-names>
</string-name>, <string-name>
<surname>Koldobskiy</surname>, <given-names>M.A.</given-names>
</string-name> &#x00026; <string-name>
<surname>Gondor</surname>, <given-names>A.</given-names>
</string-name> (<year>2016</year>) <article-title>Epigenetic modulators, modifiers and mediators in cancer aetiology and progression</article-title>. <source xml:lang="en">Nature Reviews Genetics</source>, <volume>17</volume>, <fpage>284</fpage>&#x02013;<lpage>299</lpage>.</mixed-citation></ref><ref id="bjh15155-bib-0005"><mixed-citation publication-type="journal" id="bjh15155-cit-0005">
<string-name>
<surname>Huether</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Dong</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Wu</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Parker</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Wei</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Ma</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Edmonson</surname>, <given-names>M.N.</given-names>
</string-name>, <string-name>
<surname>Hedlund</surname>, <given-names>E.K.</given-names>
</string-name>, <string-name>
<surname>Rusch</surname>, <given-names>M.C.</given-names>
</string-name>, <string-name>
<surname>Shurtleff</surname>, <given-names>S.A.</given-names>
</string-name>, <string-name>
<surname>Mulder</surname>, <given-names>H.L.</given-names>
</string-name>, <string-name>
<surname>Boggs</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Vadordaria</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Yergeau</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Song</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Becksfort</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Lemmon</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Weber</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Cai</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Dang</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Walsh</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Gedman</surname>, <given-names>A.L.</given-names>
</string-name>, <string-name>
<surname>Faber</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Easton</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Gruber</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Kriwacki</surname>, <given-names>R.W.</given-names>
</string-name>, <string-name>
<surname>Partridge</surname>, <given-names>J.F.</given-names>
</string-name>, <string-name>
<surname>Ding</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>, <given-names>R.K.</given-names>
</string-name>, <string-name>
<surname>Mardis</surname>, <given-names>E.R.</given-names>
</string-name>, <string-name>
<surname>Mullighan</surname>, <given-names>C.G.</given-names>
</string-name>, <string-name>
<surname>Gilbertson</surname>, <given-names>R.J.</given-names>
</string-name>, <string-name>
<surname>Baker</surname>, <given-names>S.J.</given-names>
</string-name>, <string-name>
<surname>Zambetti</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Ellison</surname>, <given-names>D.W.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>J.</given-names>
</string-name> &#x00026; <string-name>
<surname>Downing</surname>, <given-names>J.R.</given-names>
</string-name> (<year>2014</year>) <article-title>The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes</article-title>. <source xml:lang="en">Nature Communications</source>, <volume>5</volume>, <fpage>3630</fpage>.</mixed-citation></ref><ref id="bjh15155-bib-0006"><mixed-citation publication-type="journal" id="bjh15155-cit-0006">
<string-name>
<surname>Kuriyama</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Gale</surname>, <given-names>R.P.</given-names>
</string-name>, <string-name>
<surname>Tomonaga</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Ikeda</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Yao</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Klisak</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Whelan</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Yakir</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Ichimaru</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Sparkes</surname>, <given-names>R.S.</given-names>
</string-name> (<year>1989</year>) <article-title>CML&#x02010;T1: a cell line derived from T&#x02010;lymphocyte acute phase of chronic myelogenous leukemia</article-title>. <source xml:lang="en">Blood</source>, <volume>74</volume>, <fpage>1381</fpage>&#x02013;<lpage>1387</lpage>.<pub-id pub-id-type="pmid">2788468</pub-id></mixed-citation></ref><ref id="bjh15155-bib-0007"><mixed-citation publication-type="journal" id="bjh15155-cit-0007">
<string-name>
<surname>Lehnertz</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>Y.W.</given-names>
</string-name>, <string-name>
<surname>Boivin</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Mayotte</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Tomellini</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Chagraoui</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Lavallee</surname>, <given-names>V.P.</given-names>
</string-name>, <string-name>
<surname>Hebert</surname>, <given-names>J.</given-names>
</string-name> &#x00026; <string-name>
<surname>Sauvageau</surname>, <given-names>G.</given-names>
</string-name> (<year>2017</year>) <article-title>H3(K27M/I) mutations promote context&#x02010;dependent transformation in acute myeloid leukemia with RUNX1 alterations</article-title>. <source xml:lang="en">Blood</source>, <volume>130</volume>, <fpage>2204</fpage>&#x02013;<lpage>2214</lpage>.<pub-id pub-id-type="pmid">28855157</pub-id></mixed-citation></ref><ref id="bjh15155-bib-0008"><mixed-citation publication-type="journal" id="bjh15155-cit-0008">
<string-name>
<surname>Martincorena</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Raine</surname>, <given-names>K.M.</given-names>
</string-name>, <string-name>
<surname>Gerstung</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Dawson</surname>, <given-names>K.J.</given-names>
</string-name>, <string-name>
<surname>Haase</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Van Loo</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Davies</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Stratton</surname>, <given-names>M.R.</given-names>
</string-name> &#x00026; <string-name>
<surname>Campbell</surname>, <given-names>P.J.</given-names>
</string-name> (<year>2017</year>) <article-title>Universal patterns of selection in cancer and somatic tissues</article-title>. <source xml:lang="en">Cell</source>, <volume>171</volume>, <fpage>e1021</fpage>.</mixed-citation></ref><ref id="bjh15155-bib-0009"><mixed-citation publication-type="journal" id="bjh15155-cit-0009">
<string-name>
<surname>Maser</surname>, <given-names>R.S.</given-names>
</string-name>, <string-name>
<surname>Choudhury</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Campbell</surname>, <given-names>P.J.</given-names>
</string-name>, <string-name>
<surname>Feng</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Wong</surname>, <given-names>K.K.</given-names>
</string-name>, <string-name>
<surname>Protopopov</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>O'Neil</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Gutierrez</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Ivanova</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Perna</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Lin</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Mani</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>McNamara</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Zaghlul</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Edkins</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Stevens</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Brennan</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Martin</surname>, <given-names>E.S.</given-names>
</string-name>, <string-name>
<surname>Wiedemeyer</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Kabbarah</surname>, <given-names>O.</given-names>
</string-name>, <string-name>
<surname>Nogueira</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Histen</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Aster</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Mansour</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Duke</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Foroni</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Fielding</surname>, <given-names>A.K.</given-names>
</string-name>, <string-name>
<surname>Goldstone</surname>, <given-names>A.H.</given-names>
</string-name>, <string-name>
<surname>Rowe</surname>, <given-names>J.M.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>Y.A.</given-names>
</string-name>, <string-name>
<surname>Look</surname>, <given-names>A.T.</given-names>
</string-name>, <string-name>
<surname>Stratton</surname>, <given-names>M.R.</given-names>
</string-name>, <string-name>
<surname>Chin</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Futreal</surname>, <given-names>P.A.</given-names>
</string-name> &#x00026; <string-name>
<surname>DePinho</surname>, <given-names>R.A.</given-names>
</string-name> (<year>2007</year>) <article-title>Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers</article-title>. <source xml:lang="en">Nature</source>, <volume>447</volume>, <fpage>966</fpage>&#x02013;<lpage>971</lpage>.<pub-id pub-id-type="pmid">17515920</pub-id></mixed-citation></ref></ref-list></back></article>